Literature DB >> 30667281

Sex Differences in In-Hospital Management and Outcomes of Patients With Acute Coronary Syndrome.

Yongchen Hao1, Jing Liu1, Jun Liu1, Na Yang1, Sidney C Smith2, Yong Huo3, Gregg C Fonarow4, Junbo Ge5, Kathryn A Taubert6, Louise Morgan7, Mengge Zhou1, Yueyan Xing1, Chang-Sheng Ma8, Yaling Han9, Dong Zhao1.   

Abstract

BACKGROUND: Coronary heart disease is a leading cause of mortality among women. Systematic evaluation of the quality of care and outcomes in women hospitalized for acute coronary syndrome (ACS), an acute manifestation of coronary heart disease, remains lacking in China.
METHODS: The CCC-ACS project (Improving Care for Cardiovascular Disease in China-Acute Coronary Syndrome) is an ongoing nationwide registry of the American Heart Association and the Chinese Society of Cardiology. Using data from the CCC-ACS project, we evaluated sex differences in acute management, medical therapies for secondary prevention, and in-hospital mortality in 82 196 patients admitted for ACS at 192 hospitals in China from 2014 to 2018.
RESULTS: Women with ACS were older than men (69.0 versus 61.1 years, P<0.001) and had more comorbidities. After multivariable adjustment, eligible women were less likely to receive evidence-based acute treatments for ACS than men, including early dual antiplatelet therapy, heparins during hospitalization, and reperfusion therapy for ST-segment-elevation myocardial infarction. With respect to strategies for secondary prevention, eligible women were less likely to receive dual antiplatelet therapy, angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, statins at discharge, and smoking cessation and cardiac rehabilitation counseling during hospitalization. In-hospital mortality rate was higher in women than in men (2.60% versus 1.50%, P<0.001). The sex difference in in-hospital mortality was no longer observed in patients with ST-segment-elevation myocardial infarction (adjusted odds ratio, 1.18; 95% CI, 1.00 to 1.41; P=0.057) and non-ST-segment elevation ACS (adjusted odds ratio, 0.84; 95% CI, 0.66 to 1.06; P=0.147) after adjustment for clinical characteristics and acute treatments.
CONCLUSIONS: Women hospitalized for ACS in China received acute treatments and strategies for secondary prevention less frequently than men. The observed sex differences in in-hospital mortality were mainly attributable to worse clinical profiles and fewer evidence-based acute treatments provided to women with ACS. Specially targeted quality improvement programs may be warranted to narrow sex-related disparities in quality of care and outcomes in patients with ACS. CLINICAL TRIAL REGISTRATION: URL: https://www.clinicaltrials.gov . Unique identifier: NCT02306616.

Entities:  

Keywords:  acute coronary syndrome; in-hospital mortality; medical care research; women’s health

Year:  2019        PMID: 30667281     DOI: 10.1161/CIRCULATIONAHA.118.037655

Source DB:  PubMed          Journal:  Circulation        ISSN: 0009-7322            Impact factor:   29.690


  37 in total

1.  Implicit bias in healthcare: clinical practice, research and decision making.

Authors:  Dipesh P Gopal; Ula Chetty; Patrick O'Donnell; Camille Gajria; Jodie Blackadder-Weinstein
Journal:  Future Healthc J       Date:  2021-03

Review 2.  Update on Management of Cardiovascular Diseases in Women.

Authors:  Fabiana Lucà; Maurizio Giuseppe Abrignani; Iris Parrini; Stefania Angela Di Fusco; Simona Giubilato; Carmelo Massimiliano Rao; Laura Piccioni; Laura Cipolletta; Bruno Passaretti; Francesco Giallauria; Angelo Leone; Giuseppina Maura Francese; Carmine Riccio; Sandro Gelsomino; Furio Colivicchi; Michele Massimo Gulizia
Journal:  J Clin Med       Date:  2022-02-22       Impact factor: 4.241

3.  Sex-related differences of invasive therapy in patients with aneurysmal subarachnoid hemorrhage.

Authors:  S Y Bögli; D Utebay; N Smits; L P Westphal; L Hirsbrunner; S Unseld; E Keller; G Brandi
Journal:  Acta Neurochir (Wien)       Date:  2022-08-19       Impact factor: 2.816

4.  Yentl's Bikini: Sex Differences in STEMI.

Authors:  Martha Gulati
Journal:  J Am Heart Assoc       Date:  2019-05-21       Impact factor: 5.501

5.  Sex Differences in the Outcomes of Elderly Patients with Acute Coronary Syndrome.

Authors:  Shi Tai; Xuping Li; Hui Yang; Zhaowei Zhu; Liang Tang; Liyao Fu; Xinqun Hu; Zhenfei Fang; Yonghong Guo; Shenghua Zhou
Journal:  Cardiol Res Pract       Date:  2020-05-12       Impact factor: 1.866

6.  Sex-Specific Clinical Characteristics and Long-Term Outcomes in Patients With Myocardial Infarction With Non-obstructive Coronary Arteries.

Authors:  Side Gao; Wenjian Ma; Sizhuang Huang; Xuze Lin; Mengyue Yu
Journal:  Front Cardiovasc Med       Date:  2021-06-09

7.  Plasma-Derived Exosomal Circular RNA hsa_circ_0005540 as a Novel Diagnostic Biomarker for Coronary Artery Disease.

Authors:  Wei-Peng Wu; Yan-Hong Pan; Meng-Yun Cai; Jin-Ming Cen; Can Chen; Lei Zheng; Xinguang Liu; Xing-Dong Xiong
Journal:  Dis Markers       Date:  2020-06-30       Impact factor: 3.434

8.  A Narrative Review and Expert Panel Recommendations on Dyslipidaemia Management After Acute Coronary Syndrome in Countries Outside Western Europe and North America.

Authors:  Ashraf Reda; Wael Almahmeed; Idit Dobrecky-Mery; Po-Hsun Huang; Ursulo Juarez-Herrera; Naresh Ranjith; Tobias Sayre; Miguel Urina-Triana
Journal:  Adv Ther       Date:  2020-03-29       Impact factor: 3.845

9.  Rationale and design of the Henan ST elevation myocardial infarction (STEMI) registry: a regional STEMI project in predominantly rural central China.

Authors:  You Zhang; Shan Wang; Shuyan Yang; Shanshan Yin; Qianqian Cheng; Muwei Li; Datun Qi; Xianpei Wang; Zhongyu Zhu; Luosha Zhao; Dayi Hu; Chuanyu Gao
Journal:  BMC Cardiovasc Disord       Date:  2019-11-28       Impact factor: 2.298

10.  Gender-specific cardiovascular outcomes in patients undergoing percutaneous coronary intervention in Chinese populations.

Authors:  Juan Long; Fanfang Zeng; Lili Wang; Chen Yi; Qiying Chen; Honglei Zhao
Journal:  BMC Cardiovasc Disord       Date:  2020-06-09       Impact factor: 2.298

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.